Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM2: Venetoclax, Ibrutinib, Rituximab +/- Navitoclax in RR MCL
NCT05864742Phase 2Active, not recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Sep 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of navitoclax in mantle cell lymphoma (MCL) (2 cohorts), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Depth of MCL response (Minimal Residual Disease) at 16 weeks. Started Sep 2023; status: active, not recruiting.
02
Drugs
navitoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05864742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05864742.